Results 71 to 80 of about 260,030 (390)

Karst aquifer hazard assessment and mapping on the Classical Karst

Acta Geographica Slovenica, 2006
The article presents potential and actual sources of groundwater contamination on the Kras plateau, which is the recharge area of the Klariči karst water source that provides drinking water for the Kras plateau and Koprsko primorje.
Nataša Ravbar
doaj   +1 more source

Targeting cancer with small molecule pan-KRAS degraders

bioRxiv
Despite the high prevalence of cancers driven by KRAS mutations, to date only the G12C mutation has been clinically proven to be druggable via covalent targeting of the mutated cysteine amino acid residue (1).
J. Popow, W. Farnaby, Andreas Gollner, C. Kofink, Gerhard Fischer, Melanie Wurm, David Zollman, Andre Wijaya, Nikolai Mischerikow, Carina Hasenoehrl, Polina Prokofeva, Heribert Arnhof, Silvia Arce-Solano, Sammy Bell, Georg Boeck, E. Diers, Aileen B. Frost, Jake Goodwin-Tindall, Jale Karolyi-Oezguer, Shakil Khan, Theresa Klawatsch, M. Koegl, Roland Kousek, Barbara Kratochvil, K. Kropatsch, Arnel A Lauber, Ross McLennan, Sabine Olt, Daniel Peter, O. Petermann, Vanessa Roessler, Peggy Stolt-Bergner, Patrick Strack, Eva Strauss, N. Trainor, Vesna Vetma, C. Whitworth, Siying Zhong, Jens Quant, Harald Weinstabl, Bernhard Kuster, Peter Ettmayer, A. Ciulli   +42 more
semanticscholar   +1 more source

Comprehensive pan-cancer genomic landscape of KRAS altered cancers and real-world outcomes in solid tumors

npj Precision Oncology, 2022
Recent clinical development of KRAS inhibitors has heightened interest in the genomic landscape of KRAS -altered cancers. We performed a pan-cancer analysis of KRAS -altered samples from 426,706 adult patients with solid or hematologic malignancies using
Jessica K. Lee, S. Sivakumar, A. Schrock, R. Madison, D. Fabrizio, O. Gjoerup, J. Ross, G. Frampton, P. Napalkov, M. Montesion, J. Schutzman, X. Ye, P. Hegde, M. Nagasaka, G. Oxnard, E. Sokol, S. Ou, Zhengrong Shi   +17 more
semanticscholar   +1 more source

Factors influencing choice of chemotherapy in metastatic colorectal cancer (mCRC) [PDF]

, 2013
Management of metastatic colorectal cancer requires a multimodal approach and must be performed by an experienced, multidisciplinary expert team. The optimal choice of the individual treatment modality, according to disease localization and extent, tumor
BASSO, ENRICO, CARUSO, DAVIDE, EVANGELISTA, SALVATORE, Foteini Vakiarou, G. Rinaldi, L. Bianchi, Lo Russo, Giuseppe, PAPA, ANSELMO, Perrone-congedi, Francesca, PRETE, ALESSANDRA ANNA, ROSSI, Luigi, SPINELLI, GIAN PAOLO, Stati, Valeria, TOMAO, SILVERIO, VERRICO, MONICA, ZORATTO, federica   +15 more
core   +1 more source

Institutional and Legal Arrangements for the Macro-prudential Supervision Activities of the Financial Stability Committee

Politeja
The article is devoted to the Financial Stability Committee, which bridged the institutional gap that emerged after the 2008 crisis. The purpose of the paper is to analyse its institutional and legal capacity for macro-prudential supervision.
Ireneusz Kraś
doaj   +1 more source

The role of KRAS and NRAS mutation detection in determining the therapy strategy for colorectal cancer

Вестник медицинского института «Реавиз»: Реабилитация, врач и здоровье, 2022
Colorectal cancer is one of the most frequently diagnosed malignant tumors in men and women, which is a highly heterogeneous group of neoplasms consisting of subclasses with different molecular and clinical characteristics, and, as a consequence ...
A. N. Toropovskiy, A. G. Nikitin, D. A. Viktorov, A. V. Solov'ev, R. M. Khuzina, O. N. Pavlova   +5 more
doaj   +1 more source

Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1

Nature, 2009
The proto-oncogene KRAS is mutated in a wide array of human cancers, most of which are aggressive and respond poorly to standard therapies. Although the identification of specific oncogenes has led to the development of clinically effective, molecularly ...
D. Barbie, P. Tamayo, J. Boehm, S. Kim, S. Moody, I. Dunn, Anna C. Schinzel, P. Sandy, E. Meylan, C. Scholl, S. Fröhling, Edmond M. Chan, M. Sos, K. Michel, C. Mermel, S. Silver, B. Weir, J. Reiling, Qing Sheng, Piyush B. Gupta, R. Wadlow, R. Wadlow, Hanh Le, S. Hoersch, Ben S. Wittner, Ben S. Wittner, Sridhar Ramaswamy, Sridhar Ramaswamy, D. Livingston, D. Sabatini, M. Meyerson, M. Meyerson, Roman K. Thomas, E. Lander, J. Mesirov, D. Root, D. Gilliland, T. Jacks, W. Hahn   +38 more
semanticscholar   +1 more source

Autophagy-dependent ferroptosis drives tumor-associated macrophage polarization via release and uptake of oncogenic KRAS protein

Autophagy, 2020
KRAS is the most frequently mutated oncogene in human neoplasia. Despite a large investment to understand the effects of KRAS mutation in cancer cells, the direct effects of the oncogenetic KRAS activation on immune cells remain elusive.
Enyong Dai, Leng Han, Jiao Liu, Yangchun Xie, G. Kroemer, D. Klionsky, H. Zeh, R. Kang, Jing Wang, D. Tang   +9 more
semanticscholar   +1 more source

KRAS mutation in pancreatic cancer.

Seminars in Oncology, 2021
Pancreatic cancer is a recalcitrant cancer with one of the lowest 5-year survival rates. A hallmark of pancreatic cancer is the prevalence of oncogenic mutation in the KRAS gene.
Ji Luo
semanticscholar   +1 more source

A pilot study evaluating concordance between blood-based and patient-matched tumor molecular testing within pancreatic cancer patients participating in the Know Your Tumor (KYT) initiative [PDF]

, 2016
Recent improvements in next-generation sequencing (NGS) technology have enabled detection of biomarkers in cell-free DNA in blood and may ultimately replace invasive tissue biopsies.
Aberra, Metasebia, Bender, R. Joseph, Brody, Jonathan, Chung, Vincent, Heartwell, Craig, Hendifar, Andrew, Hoos, William A., Madhavan, Subha, Mason, Kimberly, Matrisian, Lynn M., Mikhail, Sam, Petricoin, Emanuel, III, Picozzi, Vincent, Pishvaian, Michael J., Rahib, Lola, Varieur, Katelyn   +15 more
core   +2 more sources